Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors

Dario Cattaneo, Giuseppe Remuzzi

Research output: Contribution to journalArticle

Abstract

Observational studies in different populations indicate a positive relationship between dyslipidemia, cardiovascular events, and kidney disease progression. Patients with chronic renal diseases usually present with conditions (inflammation, oxidative stress) that can induce quantitative and qualitative changes in lipoprotein composition, making these particles more atherogenic. Several large randomized trials have shown that lowering cholesterol with statins reduces coronary mortality and morbidity across a wide range of cholesterol levels. Moreover, statins ameliorated renal function and structure in experimental models of progressive renal disease as well as in patients with proteinuric disease. It has been hypothesized that statins may directly modulate intracellular signaling systems involved in cellular proliferation, inflammatory, and fibrogenic responses. In addition, studies in animals have shown that the mevalonate pathway also may be involved in the regulation of the renin-angiotensin system, providing the rationale for the use of statins in combination with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor antagonists, 2 classes of drugs that have evidenced beneficial effects in different forms of renal diseases. Preliminary studies have shown that a multidrug approach may induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients whose condition does not fully respond to a single treatment.

Original languageEnglish
Pages (from-to)71-76
Number of pages6
JournalJournal of Renal Nutrition
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 2005

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
kidney diseases
anti-inflammatory activity
Angiotensin-Converting Enzyme Inhibitors
Oxidative Stress
Anti-Inflammatory Agents
oxidative stress
Kidney
Lipids
lipids
Cholesterol
cholesterol
renin-angiotensin system
Mevalonic Acid
angiotensin II
Angiotensin Receptor Antagonists
Kidney Diseases
remission
hyperlipidemia
observational studies

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Urology
  • Food Science
  • Clinical Neurology

Cite this

Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. / Cattaneo, Dario; Remuzzi, Giuseppe.

In: Journal of Renal Nutrition, Vol. 15, No. 1, 01.2005, p. 71-76.

Research output: Contribution to journalArticle

@article{e71ea54153804fc682b1b1fb1d6d0c04,
title = "Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors",
abstract = "Observational studies in different populations indicate a positive relationship between dyslipidemia, cardiovascular events, and kidney disease progression. Patients with chronic renal diseases usually present with conditions (inflammation, oxidative stress) that can induce quantitative and qualitative changes in lipoprotein composition, making these particles more atherogenic. Several large randomized trials have shown that lowering cholesterol with statins reduces coronary mortality and morbidity across a wide range of cholesterol levels. Moreover, statins ameliorated renal function and structure in experimental models of progressive renal disease as well as in patients with proteinuric disease. It has been hypothesized that statins may directly modulate intracellular signaling systems involved in cellular proliferation, inflammatory, and fibrogenic responses. In addition, studies in animals have shown that the mevalonate pathway also may be involved in the regulation of the renin-angiotensin system, providing the rationale for the use of statins in combination with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor antagonists, 2 classes of drugs that have evidenced beneficial effects in different forms of renal diseases. Preliminary studies have shown that a multidrug approach may induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients whose condition does not fully respond to a single treatment.",
author = "Dario Cattaneo and Giuseppe Remuzzi",
year = "2005",
month = "1",
doi = "10.1053/j.jrn.2004.09.029",
language = "English",
volume = "15",
pages = "71--76",
journal = "Journal of Renal Nutrition",
issn = "1051-2276",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors

AU - Cattaneo, Dario

AU - Remuzzi, Giuseppe

PY - 2005/1

Y1 - 2005/1

N2 - Observational studies in different populations indicate a positive relationship between dyslipidemia, cardiovascular events, and kidney disease progression. Patients with chronic renal diseases usually present with conditions (inflammation, oxidative stress) that can induce quantitative and qualitative changes in lipoprotein composition, making these particles more atherogenic. Several large randomized trials have shown that lowering cholesterol with statins reduces coronary mortality and morbidity across a wide range of cholesterol levels. Moreover, statins ameliorated renal function and structure in experimental models of progressive renal disease as well as in patients with proteinuric disease. It has been hypothesized that statins may directly modulate intracellular signaling systems involved in cellular proliferation, inflammatory, and fibrogenic responses. In addition, studies in animals have shown that the mevalonate pathway also may be involved in the regulation of the renin-angiotensin system, providing the rationale for the use of statins in combination with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor antagonists, 2 classes of drugs that have evidenced beneficial effects in different forms of renal diseases. Preliminary studies have shown that a multidrug approach may induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients whose condition does not fully respond to a single treatment.

AB - Observational studies in different populations indicate a positive relationship between dyslipidemia, cardiovascular events, and kidney disease progression. Patients with chronic renal diseases usually present with conditions (inflammation, oxidative stress) that can induce quantitative and qualitative changes in lipoprotein composition, making these particles more atherogenic. Several large randomized trials have shown that lowering cholesterol with statins reduces coronary mortality and morbidity across a wide range of cholesterol levels. Moreover, statins ameliorated renal function and structure in experimental models of progressive renal disease as well as in patients with proteinuric disease. It has been hypothesized that statins may directly modulate intracellular signaling systems involved in cellular proliferation, inflammatory, and fibrogenic responses. In addition, studies in animals have shown that the mevalonate pathway also may be involved in the regulation of the renin-angiotensin system, providing the rationale for the use of statins in combination with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor antagonists, 2 classes of drugs that have evidenced beneficial effects in different forms of renal diseases. Preliminary studies have shown that a multidrug approach may induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients whose condition does not fully respond to a single treatment.

UR - http://www.scopus.com/inward/record.url?scp=11844258767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11844258767&partnerID=8YFLogxK

U2 - 10.1053/j.jrn.2004.09.029

DO - 10.1053/j.jrn.2004.09.029

M3 - Article

C2 - 15648011

AN - SCOPUS:11844258767

VL - 15

SP - 71

EP - 76

JO - Journal of Renal Nutrition

JF - Journal of Renal Nutrition

SN - 1051-2276

IS - 1

ER -